1.Clinical Study on Naomaitai Capsule for Treatment of 50 Cases with Sequelae of Apoplexy
Journal of Traditional Chinese Medicine 1992;0(08):-
Objective:To probe clinical therapeutic effect of Naornaitai Capsule on sequelae of apoplexy.Methods:92 cases with sequelae of apoplexy were randomly divided into two groups,the treatment group(n=50)treated by oral administration of Naomaitai Capsule and the control group(n=42)by Xinnao Shutong Capsule.Their therapeutic effects were assessed at the end of 2 therapeutic courses,4 weeks constituting one course.Results:The total effective rate was 90.0% in the treatment group and 71.4% in the control group,the treatment group being superior to the control group(P
2.Effects of Danggui-beimu-kushen Pill on expression of PCNA, bcl-2 and bax in BPH mice model
Qifeng ZHANG ; Zongxuan HUANG ; Guozheng GAO ; Tiehao HE
International Journal of Traditional Chinese Medicine 2011;33(2):125-127
Objective To study the effect of Danggui-beimu-kushen Pill on benign prostatic hyperplasia (BPH) and its possible mechanism. Methods BPH model mouse was produced by intraperitoneal injection of testosterone propionate. The high, medium and low dose treatment group was fed high, middle and low dose of Danggui-beimu-kushen Pill respectively, while the positive control group was fed Qianliekang liquid, 600 mg/kg. All mice were executed on the 21 day. Such values were observed as the prostate index changes, pathological changes of prostate by HE staining light microscopy and the expression changes of PCNA,bcl-2 and bax by immunohistochemistry. Results The prostate index of the treatment group was lower than the model group; the PCNA and bcl-2 expression were lower than the model group, while the bax expression was higher than the model group. Meanwhile; there is no significant difference among the treatment groups.Moreover, the difference between the treatment groups and the positive control group has no statistic meaning.Conclusion Danggui-beimu-kushen Pill can suppress BPH in mice. The mechanism may be related to the reduction expression of cell-proliferation protein PCNA and apoptosis profilin bcl-2, and the increase of bax expression.